EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

BCL6B Contributes to Ocular Vascular Diseases via Notch Signal Silencing

Miruto Tanaka, Shinsuke Nakamura, Tomohisa Sakaue, Takumi Yamamoto, Masashi Maekawa iD, Anri Nishinaka, Hiroto Yasuda, Kaori Yunoki, Yuji Sato, Masaaki Sawa iD, Kohichiro Yoshino, Masamitsu Shimazawa und 4 weitere

Arteriosclerosis, Thrombosis, and Vascular Biology · 2023

DOI: 10.1161/atvbaha.123.318987 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023. Verfasst von Miruto Tanaka und 15 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Japan (M.T., S.N., T.Y., A.N., H.Y., M.S., H.H.). Hauptthemen laut MEDLINE: Choroidal Neovascularization, Nucleic Acids, Retinal Neovascularization, Vascular Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Endothelial cell activation is tightly controlled by the balance between VEGF (vascular endothelial cell growth factor) and Notch signaling pathway. VEGF destabilizes blood vessels and promotes neovascularization, which are common features of sight-threatening ocular vascular disorders. Here, we show that BCL6B (B-cell CLL/lymphoma 6 member B protein), also known as BAZF, ZBTB28, and ZNF62, plays a pivotal role in the development of retinal edema and neovascularization.

Methods

The pathophysiological physiological role of BCL6B was investigated in cellular and animal models mimicking 2 pathological conditions: retinal vein occlusion and choroidal neovascularization. An in vitro experimental system was used in which human retinal microvascular endothelial cells were supplemented with VEGF. Choroidal neovascularization cynomolgus monkey model was generated to investigate the involvement of BCL6B in the pathogenesis. Mice lacking BCL6B or treated with BCL6B-targeting small-interfering ribose nucleic acid were examined for histological and molecular phenotypes.

Results

In retinal endothelial cells, the BCL6B expression level was increased by VEGF. BCL6B-deficient endothelial cells showed Notch signal activation and attenuated cord formation via blockage of the VEGF-VEGFR2 signaling pathway. Optical coherence tomography images showed that choroidal neovascularization lesions were decreased by BCL6B-targeting small-interfering ribose nucleic acid. Although BCL6B mRNA expression was significantly increased in the retina, BCL6B-targeting small-interfering ribose nucleic acid suppressed ocular edema in the neuroretina. The increase in proangiogenic cytokines and breakdown of the inner blood-retinal barrier were abrogated in BCL6B knockout (KO) mice via Notch transcriptional activation by CBF1 (C promotor-binding factor 1) and its activator, the NICD (notch intracellular domain). Immunostaining showed that Müller cell activation, a source of VEGF, was diminished in BCL6B-KO retinas.

Conclusions

These data indicate that BCL6B may be a novel therapeutic target for ocular vascular diseases characterized by ocular neovascularization and edema.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Choroidal NeovascularizationNucleic AcidsRetinal NeovascularizationVascular DiseasesAnimalsHumansMiceEndothelial CellsMacaca fascicularisRiboseVascular Endothelial Growth Factor ARepressor Proteins

Stichwörter der Autor:innen

VEGFage-related macular degenerationangiogenesisedemaneovascularizationnotch

Substanzen

Nucleic AcidsRiboseVascular Endothelial Growth Factor ABcl6b protein, mouseRepressor ProteinsBCL6B protein, human

Autor:innen und Institutionen

  • Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Japan (M.T., S.N., T.Y., A.N., H.Y., M.S., H.H.).
  • Division of Cell Growth and Tumor Regulation, Proteo-Science Center, Ehime University, Japan (T.S., S.H.).
  • Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine, Japan (T.S.).
  • Division of Physiological Chemistry and Metabolism, Graduate School of Pharmaceutical Sciences, Keio University, Minato‑ku, Tokyo, Japan (M.M.).
  • Carna Biosciences, Inc., Kobe, Japan (K. Yunoki, Y.S., M.S., K. Yoshino).
  • Laboratory of Collaborative research for Innovative Drug Discovery, Gifu Pharmaceutical University, Japan (M.S.).

ORCID-Profile: Masashi Maekawa, Masaaki Sawa, Hideaki Hara

Zitieren

APA

Tanaka, M., Nakamura, S., Sakaue, T., Yamamoto, T., Maekawa, M., Nishinaka, A., Yasuda, H., Yunoki, K., Sato, Y., Sawa, M., Yoshino, K., Shimazawa, M., Hatano, M., Tokuhisa, T., Higashiyama, S., & Hara, H. (2023). BCL6B Contributes to Ocular Vascular Diseases via Notch Signal Silencing. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.123.318987

Vancouver

Tanaka M, Nakamura S, Sakaue T, Yamamoto T, Maekawa M, Nishinaka A, et al. BCL6B Contributes to Ocular Vascular Diseases via Notch Signal Silencing. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023. doi:10.1161/atvbaha.123.318987

BibTeX
@article{Tanaka2023,
  author = {Tanaka, Miruto and Nakamura, Shinsuke and Sakaue, Tomohisa and Yamamoto, Takumi and Maekawa, Masashi and Nishinaka, Anri and Yasuda, Hiroto and Yunoki, Kaori and Sato, Yuji and Sawa, Masaaki and Yoshino, Kohichiro and Shimazawa, Masamitsu and Hatano, Masahiko and Tokuhisa, Takeshi and Higashiyama, Shigeki and Hara, Hideaki},
  title = {BCL6B Contributes to Ocular Vascular Diseases via Notch Signal Silencing},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2023},
  doi = {10.1161/atvbaha.123.318987}
}
Kostenlos starten →